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OBJECTIVE: To determine the prevalence of sicca symptoms, dry eye, and secondary Sjo¨gren’s syndrome and to
evaluate the severity of dry eye in patients with mixed connective tissue disease.
METHODS: In total, 44 consecutive patients with mixed connective tissue disease (Kasukawa’s criteria) and 41
healthy controls underwent Schirmer’s test, a tear film breakup time test, and ocular surface staining to
investigate dry eye. In addition, the dry eye severity was graded. Ocular and oral symptoms were assessed using
a structured questionnaire. Salivary gland scintigraphy was performed in all patients. Classification of secondary
Sjo¨gren’s syndrome was assessed according to the American-European Consensus Group criteria.
RESULTS: The patients and controls had comparable ages (44.7¡12.4 vs. 47.2¡12.2 years) and frequencies of
female gender (93 vs. 95%) and Caucasian ethnicity (71.4 vs. 85%). Ocular symptoms (47.7 vs. 24.4%) and oral
symptoms (52.3 vs. 9.7%) were significantly more frequent in patients than in controls. Fourteen (31.8%)
patients fulfilled Sjo¨gren’s syndrome criteria, seven of whom (50%) did not have this diagnosis prior to study
inclusion. A further comparison of patients with mixed connective tissue disease with or without Sjo¨gren’s
syndrome revealed that the former presented significantly lower frequencies of polyarthritis and cutaneous
involvement than did the patients without Sjo¨gren’s syndrome. Moderate to severe dry eye was found in 13 of
14 patients with mixed connective tissue disease and Sjo¨gren’s syndrome (92.8%).
CONCLUSIONS: Sjo¨gren’s syndrome, particularly with moderate to severe dry eye, is frequent in patients with
mixed connective tissue disease. These findings alert the physician regarding the importance of the appropriate
diagnosis of this syndrome in such patients.
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& INTRODUCTION
Mixed connective tissue disease (MCTD) is an inflamma-
tory disease characterized by combined features of systemic
lupus erythematosus (SLE), systemic sclerosis (SSc), and
polymyositis (PM) that is associated with high serum titers
of antibody to extractable nuclear antigen, with a specificity
for nuclear ribonucleoprotein (1). The large spectrum of
clinical signs and symptoms of MCTD includes sicca
symptoms and Sjo¨gren’s syndrome (SS). However, the
actual frequencies of dry eye and SS in MCTD patients are
poorly characterized (2,3).
Dry eye, or keratoconjunctivitis sicca, is a multifactorial
condition that affects the tear film and ocular surface due
to abnormalities in the quality or quantity of the tear film. This
condition is accompanied by an increase in the film’s
osmolarity and inflammation of the ocular surface (4). Dry
eye is commonly observed in systemic autoimmune disorders,
such as primary SS (pSS), rheumatoid arthritis (RA), SLE, and
SSc (4-6). This condition is characterized by symptoms of
ocular irritation and discomfort, which affect functional visual
acuity and the ability to work, read, use a computer, and drive
at night (7,8). Dry eye also increases the risk of eye infection
and destruction of ocular tissue (9). Millions of people
worldwide suffer from dry eye, and currently, recognition of
the magnitude of the disease and knowledge of its pathogen-
esis and treatment are changing (9-12).
SS affects exocrine glands by lymphocytic infiltration,
causing stomatitis and dry eye (13). SS may occur alone as
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pSS or may accompany other autoimmune disorders as
secondary SS (14). Data regarding dry eye and secondary SS
in MCTD are scarce in the literature, with a prevalence
ranging from 14.5 to 56% (3,15). The few available studies
were retrospective, without a control group or strict
exclusion criteria (1-3,16,17), precluding a definitive conclu-
sion about their findings. In addition, there are no data
regarding the severity of dry eye according to established
criteria in MCTD patients. These aspects are important
because dry eye and SS may have a significant impact on the
quality of life and treatment of MCTD patients.
The aim of this study was therefore to determine the
prevalence of sicca symptoms, dry eye, and secondary SS
and to evaluate the severity of dry eye in MCTD patients.
& PATIENTS AND METHODS
Patients
This cross-sectional study included 44 consecutive patients
with MCTD who were followed at the Rheumatology
Division of the Hospital das Clı´nicas da Faculdade de
Medicina da Universidade de Sa˜o Paulo. This tertiary referral
hospital is linked to a university center. All patients fulfilled
the MCTD classification criteria of Kasukawa et al. (18), with
at least one of the following common symptoms: 1)
Raynaud’s phenomenon or swollen fingers or hands; 2) the
presence of anti-U1RNP; and 3) one or more findings in at
least two of three categories, including SLE-like (polyarthritis,
pericarditis/pleuritis, lymphadenopathy, facial erythema,
and leukopenia/thrombocytopenia), scleroderma-like (scler-
odactyly, pulmonary fibrosis, and esophageal dysmotility),
and polymyositis-like (muscle weakness, high creatine
phosphokinase levels and myopathic electroneuromyogra-
phy). The patients tested persistently negative for anti-
dsDNA and anti-Sm antibodies. Patients with a history of
current use of xerogenic drugs, head and neck radiation
treatment, hepatitis B/C, acquired immunodeficiency syn-
drome (AIDS), preexisting lymphoma, sarcoidosis, or graft-
versus-host disease were not included (19). In addition,
smokers and patients receiving hormonal replacement
therapy were excluded.
Controls
In total, 41 healthy volunteer controls with a comparable
mean age and gender distribution and with the same
exclusion criteria were evaluated for dry eye. The local
research ethics committee approved the study, and informed
consent was obtained from all patients and controls.
Clinical and laboratorial data
A general evaluation collected data on age, gender, race,
disease duration, and medications in current use (oral
prednisone and/or cytotoxic drugs). The clinical aspects of
MCTD that were evaluated were a SD-pattern in nailfold
capillaroscopy, hypergammaglobulinemia (gammaglobul-
in.1.6 g/dl), esophageal involvement (determined by
high-resolution computerized tomography or an esopha-
gram), polyarthritis (arthritis involving five or more
peripheral joints), muscle disease (muscle weakness asso-
ciated with an elevation of creatine phosphokinase and/or
aldolase levels in the absence of thyroid disease, infections
or myopathy-inducing drugs) and cutaneous disease (SLE
manifestation of malar rash or photosensitivity or SSc
manifestation of sclerodactyly). Demographic and clinical/
laboratorial features, including a previous diagnosis of SS,
were obtained from the ongoing electronic database at 1- to
6-month intervals for 128 MCTD patients followed by our
Rheumatology Division since 2001.
A questionnaire regarding ocular and oral symptoms
according to the American-European Consensus Group
classification criteria for SS was applied (AECG) (19). Sicca
symptoms were defined as the presence of ocular dryness
(daily persistent dry eyes, a recurrent sensation of sand and
gravel in the eyes, and/or the use of tear substitutes more
than three times per day) and oral dryness (a daily feeling of
dry mouth, recurrent or persistently swollen salivary
glands, and/or frequent drinking of liquids to aid in
swallowing dry food) (19).
Salivary gland scintigraphy was performed in all MCTD
patients to investigate salivary concentration and secretion
abnormalities. A serologic evaluation examined the expres-
sion of rheumatoid factor (by latex fixation assay) and anti-
Ro/SSA and anti-La/SSB antibodies (by counterimmunoe-
lectrophoresis), as previously described (20,21).
An ophthalmic evaluation performed at the Ophthal-
mologic Department of Hospital das Clı´nicas da Faculdade
de Medicina da Universidade de Sa˜o Paulo included the
following: Schirmer’s I test without anesthetic to evaluate
aqueous tear production, a tear breakup time (BUT) test to
measure tear film stability, and tests for the evaluation of
epithelial ocular surface integrity by diagnostic dyes. These
dyes included a fluorescein 1% eyedrop for the corneal area
and a rose bengal 1% eyedrop for the conjunctiva. The
cornea was divided into three areas (superior, central, and
inferior), and each area’s staining with the fluorescein dye
was scored from 0 to 3 (with the total ranging from 0 to 9) if
epitheliopathy was present. The conjunctiva was also
divided into three areas (nasal, central, and temporal),
whose staining with the rose bengal eyedrop was assessed
using the same score as for fluorescein. All MCTD patients
and volunteer controls were examined under the same
conditions of room temperature and humidity (medians
21.5 C˚ and 65%, respectively) (4,5).
Dry eye severity was classified using the grading scheme of
Behrens et al. (6), based on scoring of symptoms and clinical
signs. The levels of severity ranged from 1 to 4: level 1 (mild):
mild symptoms, no conjunctival or corneal staining and
variable values of BUT (sec) and on Schirmer’s test (mm/
5 min); level 2 (moderate): moderate symptoms, variable
scores for conjunctival and corneal staining, a BUT #10 sec
and Schirmer’s test score#10 mm/5 min; level 3 (moderate/
severe): severe or frequent symptoms, moderate to marked
conjunctival and corneal staining, a BUT #5 sec and
Schirmer’s test score #5 mm/5 min; and level 4 (severe):
severe symptoms, severe conjunctival and corneal staining,
immediate BUT and Schirmer’s test score #2 mm/5 min.
The revised AECG criteria for SS were applied. The
presence of item I (ocular symptoms) or item II (oral
symptoms) plus items III (objective evidence of ocular
involvement) and V (objective evidence of salivary gland
involvement) is considered to be indicative of secondary SS
(19). It is noteworthy that to be classified as having
secondary SS, patients must present ocular or oral symp-
toms and ocular and oral objective signs (19).
Statistical analysis
The results are presented as the mean and standard
deviation for continuous variables and as the frequency (%)
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for categorical variables. To evaluate differences between
patients and controls, for continuous variables, we used a
t test or Mann-Whitney test. For categorical variables,
differences were assessed by a chi-square test or Fisher’s
exact test. Dunn’s test and a Kruskal-Wallis test were used
for nonparametric test data. The McNemar symmetry test
was applied to evaluate patients diagnosed with secondary
SS according to the AECG criteria and to compare them
to the group of patients who had a previous SS diagnosis.
Values were considered statistically significant when
p,0.05.
& RESULTS
Demographic features of MCTD patients and
controls
The MCTD patients and controls were of a similar age
(44.7¡12.4 [range 22 to 67 years] vs. 47.2¡12.2 [range 23 to
70 years] years; p= 0.3) and presented similar frequencies of
female gender (93 vs. 95%; p= 1.0) and Caucasian ethnicity
(71.4 vs. 85%; p= 0.1).
Clinical and therapeutic features of MCTD patients
The mean disease duration was 10.8¡7.3 years (range 2
to 35 years). Sixteen (36.4%) patients were using cytotoxic
drugs (azathioprine, cyclophosphamide, or methotrexate),
and 10 (22.7%) patients were receiving high dosages of oral
prednisone (.20 mg per day). Serum anti-Ro/SSA anti-
bodies were detected in 29.5% of patients, whereas only 1
(2.3%) had a positive result for anti-La/SSB antibodies.
Rheumatoid factor was positive in 18 of 44 (40.9%) patients.
Sicca symptoms
In total, 21 (47.7%) patients had at least one ocular
symptom of dry eye (item I of the AECG criteria for SS). Of
these patients, 20 (45.5%) patients had daily and persistently
troublesome dry eyes for more than 3 months, and 8 (18.2%)
patients had a recurrent sensation of sand or gravel in their
eyes. The same percentage of patients used tear substitutes
more than three times per day (Table 1).
Concerning oral symptoms, 23 (52.3%) patients presented
at least one positive symptom for dry mouth (item II of the
AECG criteria for SS). Of these patients, 22 (50%) patients
had a daily feeling of dry mouth for more than 3 months,
and 8 (18.2%) patients had recurrent or persistent swollen
salivary glands as an adult. Additionally, 12 (27.3%) patients
frequently drank liquids to aid in swallowing dry foods.
Sicca symptoms (dry eye and dry mouth) were present in
17 (38.6%) patients (Table 1). Symptoms of dry eye (47.7 vs.
24.4%) and dry mouth (52.3 vs. 9.7%) were significantly
more frequent in patients than in controls (p= 0.02 and
p= 0.001, respectively).
Ocular and oral involvement
There was objective evidence of ocular involvement
(Schirmer’s I test #5 mm/5 min or rose bengal staining
score $4) in 52.3% of patients (Schirmer’s I test #5 mm/
5 min was positive in 43.2% of patients, and a rose bengal
staining score $4 was observed in 27.3% of patients)
(Table 1).
Objective evidence of salivary gland involvement, as
determined by scintigraphy (item V), was positive in 70.4%
of MCTD patients.
According to the dry eye severity grading scheme, 19 of
44 (43.2%) MCTD patients had level 1 (mild), 12 of 44
(27.3%) had level 2 (moderate), 4 of 44 (9.1%) had level 3
(moderate/severe), and 3 of 44 (6.8%) had level 4 (severe) of
severity (Table 2). In the control group, there was only 1
(2.4%) person with moderate dry eye (level 2), and 12
(29.3%) presented mild dry eye (level 1) (Table 2). All
diagnostic dry eye tests performed in MCTD patients
presented mean ¡ standard deviation values that were
significantly different from those of the control group
(Table 1).
Sjo¨gren’s syndrome
The frequency of secondary SS according to the revised
AECG classification criteria was 31.8% of MCTD patients
(n = 14), and 7 (50%) did not have this diagnosis prior to
study inclusion (p,0.001). Moderate to severe dry eye was
found in 13 of 14 patients with SS (92.8%). Concerning non-
SS patients (n = 30), 80% of patients had dry eye (63.3% with
mild dry eye and 16.7% with moderate dry eye).
Table 1 - Sicca symptoms and dry eye evaluation in MCTD
patients and controls.
MCTD (n=44) Control (n = 41) p-value
Ocular symptoms (%) 21 (47.7) 10 (24.4) 0.02
Oral symptoms (%) 23 (52.3) 4 (9.7) 0.001
Ocular+oral symptoms (%) 17 (38.6) 4 (9.7) 0.002
Schirmer’s test
#5 mm/5 min; n (%) 19 (43.2) 3 (7.3) 0.001
Mean ¡ SD (mm/5 min) 10.5¡8.8 22.9¡11.0 0.001
BUT
,10 sec; n (%) 35 (79.5) 29 (70.7) 0.3
Mean ¡ SD (sec) 7.7¡3.3 9.3¡5.4 0.05
Fluorescein
$4 score; n (%) 12 (27.3) 0 (0) 0.08
Mean ¡ SD (score) 0.7¡0.8 0.07¡0.26 0.001
Rose bengal
$4 score; n (%) 12 (27.3) 0 (0) 0.001
Mean ¡ SD (score) 2.8¡2.3 0.1¡0.2 0.001
Sicca symptoms: ocular and oral symptoms. MCTD: mixed connective
tissue disease. p-value,0.05.
Table 2 - Severity grading of dry eyes in MCTD patients
and controls.
MCTD (n=44) Control (n = 41) p-value
Moderate/severe n (%) 19 (43.2) 1 (2.4)
Schirmer’s test (mm/5 min) 5.9¡4.6 8.0 NA
BUT (sec) 7.1¡2.7 7.0 NA
Fluorescein (score) 1.1¡0.9 1.0 NA
Rose bengal (score) 4.1¡2.5 1.0 NA
Mild n (%) 19 (43.2) 12 (29.3)
Schirmer’s test (mm/5 min) 12.0¡8.9 16.9¡11.8 0.2
BUT (sec) 6.7¡3.7 7.5¡5.3 0.8
Fluorescein (score) 0.3¡0.6 0.1¡0.3 0.1
Rose bengal (score) 2.3¡1.6 0.2¡0.4 0.001
Normal n (%) 6 (13.6) 28 (68.3)
Schirmer’s test (mm/5 min) 20.0¡10.5 26.0¡9.4 0.2
BUT (sec) 9.7¡3.4 10.3¡5.4 1.0
Fluorescein (score) 0.2¡0.4 0.1¡0.2 0.2
Rose bengal (score) 0.7¡0.5 0.0¡0.0 0.001
MCTD: mixed connective tissue disease; BUT: breakup time. Moderate/
severe dry eye = levels 2, 3, and 4; mild dry eye = level 1; normal =
without dry eye. The values are expressed as the mean ¡ standard
deviation. p-value,0.05. NA: not available (n = 1 in control group).
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A further comparative analysis of MCTD patients with
and without SS revealed that polyarthritis (64.3 vs. 93.3%,
p= 0.02) and cutaneous disease (35.7 vs. 70.0%, p= 0.03) were
less frequent in patients with SS (Table 3). Disease duration,
age, esophageal involvement, muscle disease, SD-pattern
in nailfold capillaroscopy, hypergammaglobulinemia, anti-
Ro/SSA expression, anti-La/SSB expression, and rheuma-
toid factor expression were similar in MCTD patients with
and without SS. The use of prednisone at a dosage above
20 mg/day and of cytotoxic drugs did not differ between
the two groups (Table 3).
& DISCUSSION
In the present study, the authors identified dry eye, sicca
symptoms, and SS as frequently associated conditions in
MCTD patients.
The prevalence of dry eye in the normal population is
generally 5% to 17% (10). In the present study, approximately
half of MCTD patients had this condition, with a frequency
similar to frequencies reported in SLE (31% to 76%) and SSc
(38% to 81%) (1,22-24). Importantly, we used strict selection
criteria for MCTD (18), and the inclusion of an age- and
gender-matched healthy control group improved the accu-
racy of our findings because these factors strongly influence
the frequencies of sicca symptoms and dry eye (8).
Data from this study also allowed the classification of dry
eye severity (6) because a thorough investigation of this
condition was performed, including the application of a
standardized sicca syndrome questionnaire (19). In addition,
the use of the severity grading scheme, which included both
symptoms and objective findings (clinical evaluation and
diagnostic tests), increased the frequency of dry eye
diagnosis (86.4%) compared with the assessment of ocular
symptoms (47.7%) or objective evidence of ocular involve-
ment (52.3%) alone, most likely yielding a better diagnostic
accuracy than clinical and objective evaluations together (19).
In this regard, we emphasize that dry eye has an important
impact on the ability to perform daily activities, even in mild
to moderate cases (25). This is the first study in the literature
that has applied severity criteria to patients with MCTD.
Furthermore, dry eye severity grading has not been reported
for other rheumatic autoimmune diseases, such as SLE and
SSc (26,27). Our findings show that moderate to severe dry
eye is frequent in MCTD patients and indicate the importance
of making this diagnosis in MCTD patients so that a
therapeutic strategy can be established, which may improve
the conditions of the ocular surface, consequently reducing
morbidity due to dry eye (9,28).
In this study, we applied rigorous exclusion criteria, such
as the exclusion of smoking, estrogen replacement therapy,
and the use of xerogenic medications, to rule out environ-
mental factors and other risk factors known to be associated
with dry eye (8,28-31). Therefore, our findings demonstrate
the important role of MCTD itself in the development of dry
eye, suggesting the possibility that the ocular surface and
the main lacrimal gland could be target organs in the MCTD
autoimmune process (18,32).
Regarding sicca symptoms, our finding (38.6%) is compar-
able with the prevalence range reported previously (3,16,33),
although score values for both tests were not consistently
provided by authors (16). Ohtsuka et al. retrospectively
investigated salivary gland involvement by sialography and
found sialectasia in 82.1% of patients, but they did not
investigate sicca symptoms and reported the prevalence of
secondary SS to be 56.4%. The authors defined this condition
by the simultaneous presence of abnormal sialography and
clinical dry eyes (Schirmer’s I test,10 mm/5min) or dry
mouth (salivary gland secretion following citric acid stimula-
tion,10 ml/5 min) (15). Setty et al. found that 42% of MCTD
patients had sicca symptoms. However, their study was
retrospective, and the authors defined sicca symptoms as
daily dryness, frequent use of liquids due to oral dryness, and
daily ocular dryness and did not evaluate objective ocular or
oral involvement (3).
Currently, there is a trend that involves using the term
‘‘associated SS’’ instead of ‘‘secondary SS’’. However,
patients with other concomitant diffuse connective tissue
diseases, such as MCTD, are labeled by the revised AECG
criteria as having SS (19), and in these criteria, SS is classified
as primary or secondary. Thus, this designation was applied
in the present study. In this regard, according to the
definition of secondary SS established by the revised
classification criteria of the AECG (19), we observed that
nearly one-third of MCTD patients had SS. Indeed, this is
the first study applying the AECG criteria to evaluate the
prevalence of secondary SS in a population of MCTD
patients. The present evaluation also reveals that SS is often
underdiagnosed in MCTD. Efforts should be made to ensure
that this condition is not neglected because it induces a
chronic disability and is an important factor to consider when
planning treatment interventions and improvement of the
quality of a patient’s life (34). This importance is evidenced
Table 3 - Clinical features of MCTD patients with and without secondary SS.
SS n=14 Non-SS n=30 p-value
Disease duration (years) 13.0¡7.1 9.8¡7.2 0.11
Age (years) 48.6¡11.9 42.8¡12.4 0.15
Cytotoxic drugs (%) 4 (28.6) 12 (40) 0.4
Prednisone .20 mg/day (%) 3 (21.4) 7 (23.3) 1.00
SD-pattern in nailfold capillaroscopy (%) 5 (35.7) 15 (50) 0.43
Hypergammaglobulinemia (%) 13 (92.8) 23 (76.7) 0.40
Esophageal involvement (%) 11 (78.6) 23 (76.7) 1.00
Polyarthritis (%) 9 (64.3) 28 (93.3) 0.02
Muscle disease (%) 5 (35.7) 12 (40) 0.78
Cutaneous disease (%) 5 (35.7) 21 (70) 0.03
Anti-Ro/SSA (%) 5 (35.7) 8 (26.7) 0.72
Anti-La/SSB (%) 0 (0) 1 (3.3) 1.00
Positive rheumatoid factor (%) 7 (50) 11 (36.7) 0.42
MCTD: mixed connective tissue disease. p-value,0.05.
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by the moderate to severe dry eye frequently found in these
patients (92.8% in the SS group and 16.7% in the non-SS
group in comparison with 2.4% in the control group).
A limitation of our study is the lack of minor salivary
gland-related histological data. These data could perhaps
increase the rate of diagnosis of SS in MCTD, in addition to
enabling the study of possible correlations between the
intensity of the inflammatory infiltrate in salivary glands
and the intensity of sicca symptoms (19).
Interestingly, the presence of SS was associated with a
lower prevalence of cutaneous and articular manifestations
in MCTD patients, suggesting that MCTD patients with SS
could have a distinct course of the underlying disease
compared with non-SS MCTD patients, similar to what has
been reported in SLE (35). However, this finding needs to be
confirmed in future prospective studies.
In conclusion, SS is a frequently underdiagnosed condi-
tion associated with MCTD. Moderate to severe dry eye was
found in the majority of patients with SS. These data justify
the need for a systematic investigation of the exocrine
glands in MCTD to achieve early diagnosis and to develop a
treatment for improving the quality of life of patients.
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